BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer
August 31, 2023
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...